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Abstract
Background: Previous results have shown that in rats with non-ascitic cirrhosis there is an altered transport of sugars
and amino acids associated with elongated microvilli. These alterations returned to normal with the administration of
Insulin-Like Growth Factor-I (IGF-I). The aims of this study were to explore the evolution of these alterations and analyse
the effect of IGF-I in rats with advanced cirrhosis and ascites. Thus, jejunal structure and nutrient transport (D-galactose,
L-leucine, L-proline, L-glutamic acid and L-cystine) were studied in rats with ascitic cirrhosis.
Methods: Advanced cirrhosis was induced by CCl4 inhalation and Phenobarbital administration for 30 weeks. Cirrhotic
animals were divided into two groups which received IGF-I or saline during two weeks. Control group was studied in
parallel. Jejunal microvilli were studied by electron microscopy. Nutrient transport was assessed in brush border
membrane vesicles using 14C or 35S-labelled subtracts in the three experimental groups.
Results: Intestinal active Na+-dependent transport was significantly reduced in untreated cirrhotic rats. Kinetic studies
showed a decreased Vmax and a reduced affinity for sugar and four amino acids transporters (expressed as an increased
Kt) in the brush border membrane vesicles from untreated cirrhotic rats as compared with controls. Both parameters
were normalised in the IGF-I-treated cirrhotic group. Electron microscopy showed elongation and fusion of microvilli
with degenerative membrane lesions and/or notable atrophy.
Conclusions: The initial microvilli elongation reported in non ascitic cirrhosis develops into atrophy in rats with
advanced cirrhosis and nutrient transports (monosaccharides and amino acids) are progressively reduced. Both
morphological and functional alterations improved significantly with low doses of IGF-I.
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Background
Disordered energy, protein metabolism and malnutrition
are complications of liver cirrhosis, especially in advanced
stages [1,2]. Although clinically significant malabsorption
of nutrients is not frequent in these conditions, low-grade
malabsorption seems to be involved in the development
of malnutrition in these patients [1-3].
Plasma levels and/or bioavailability of Insulin-like
Growth Factor-I (IGF-I), an anabolic peptide produced
mainly in the liver, are diminished in cirrhotic patients [4-
7]. Enterocytes express IGF-I receptor population [8-10].
Therefore, IGF-I levels might influence intestinal function.
All gastrointestinal secretions have IGF-I-immunoreactiv-
ity [11]. Therefore it was suggested that a deficiency of this
hormone could be involved in maldigestion/ malabsorp-
tion, leading to malnutrition in cirrhosis [12-14]. In fact,
recently published results have shown that in rats with
non-ascitic cirrhosis there is an alteration of sugars and
amino acid transport associated with elongation of micro-
villi [13,15,16]. Both morphological and functional alter-
ations returned to normal with the administration of IGF-
I, at low doses [13,15,16]. Taking into account these pre-
vious data, the purpose of this study was focused on elu-
cidating the historical progression of these alterations by
studying a series of animals with advanced cirrhosis and
ascites. Therefore the specific aims of this study were: 1) to
investigate the structure of jejunal microvilli and intesti-
nal function in rats with ascitic liver cirrhosis; and 2) to
study whether IGF-I could influence intestinal distur-
bances in advanced stages of the hepatic disease. For these
purposes, the transport of galactose, L-leucine (neutral
amino acid), L-proline (IMINO acid), L-glutamic acid
(anionic or acidic amino acid) and L-cystine (sulfurate
amino acid)- were investigated in brush border mem-
brane vesicles (BBMV) in control rats, in untreated cir-
rhotic rats and in cirrhotic rats treated with IGF-I. In
addition, electron microscopy (EM) of jejunal mucosa
was performed in the three experimental groups.
Methods
Experimental design
All procedures were performed in conformity with The
Guiding Principles for Research Involving Animals [17].
Liver cirrhosis was induced in male Wistar rats, as previ-
ously described [14,18] by CCl4 inhalation and Phenobar-
bital in drinking water (Luminal®, Bayer, Leverkusen,
Germany) (400 mg/L), for 11 weeks. Afterwards, cirrhotic
rats continued receiving CCl4 once a week (2–3 min. inha-
lation) to complete 30 weeks of CCl4 administration.
Age-matched healthy control rats (group CO, n = 10) were
studied in parallel. In the last two weeks (28 to 30) cir-
rhotic animals received subcutaneous saline (untreated
cirrhotic group, CI, n = 10) or IGF-I (2 µg × 100 g body
weight-1 × day-1, group CI+IGF, n = 10) for two weeks.
Control rats (CO) received saline during the last two
weeks of the study.
The day before starting treatment (day 0), blood was col-
lected from the retroocular plexus of all rats with capillary
tubes (70 mm, Marienfeld, Mergenheim, Germany).
Serum samples were divided into aliquots, and stored at -
20°C. At the end of the experimental period (day 15),
blood was collected again and animals were killed by
decapitation. Ascites was confirmed and measured by the
direct observation of the abdominal cavity. Jejunal sam-
ples (20 cm approx.) were immediately frozen by immer-
sion in liquid N2 and stored at -80°C, and the proximal
segment was processed by electron microscopy study. The
liver was also dissected out and samples were processed
for histological examination.
Electron microscopy
Samples from jejunum were examined by an electron
microscope operating at 60 KV (EM10C/CR, Zeiss,
Oberkochen, Germany). Two different observers (at mag-
nification × 4,000 and 10,000) evaluated randomly ten
fields from each animal and length of microvilli was
recorded blindly on photomicrographs. The arithmetic
mean of the two scores was taken as the final
measurement.
Preparation of BBMVs
BBMVs were isolated using the magnesium precipitation
method as previously described [15]. The procedure was
carried out at 0–4°C. The averted jejunum was placed in
2 mmol/l Tris-HCl (pH 7.4) containing 100 mmol/l man-
nitol, stirred for 3 min (Vibro-mixer, E-1, Sorvall), and the
scraped jejunal mucosa was removed. The mucosal sus-
pension was mixed with 10 mmol/l MgCl2 (final concen-
tration), and centrifuged at 10,000 × g (15 min). The
supernatants were centrifuged again at 26,000 × g (30
min). Pellets were resuspended in 10 mmol/l MgCl2 and
centrifuged at 26,000 × g (30 min). The final pellets were
resuspended in the desired volume of 300 mmol/l manni-
tol, 0.1 mmol/l MgSO4, 10 mmol/l Tris-HEPES buffer (pH
7.4) (load solution), so that a final protein concentration
of 8–10 mg/ml was obtained. Isolated membranes were
circled by using a N27 gauge needle. Sucrase (EC 3.2.1.48,
enterocyte apical membrane marker) and sodium-pota-
sium-ATPase (EC 3.6.1.3, enterocyte basolateral mem-
brane marker) activities were determined in BBMV
suspension [2]. Compared with the entire initial mucosal
homogenate the BBMV activities of sucrase and sodium-
potasium-ATPase were eleven and twenty fold greater and
smaller, respectively. The total protein content of BBMVs
was determined using Bradford method [19]. Vesicles
were stored in liquid N2.BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/12
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Assessment of D-galactose and amino acid uptake by 
BBMVs
Determination of nutrient uptake by BBMVs was carried
out as previously described [15,16]. Assessment of amino
acid uptake was performed at 25°C following the rapid
filtration technique described by Hopfer et al. [20] with
few modifications. BBMV suspension (5 µl) was added to
the incubation medium (45 µl) containing 1 mmol/l of
unlabeled amino acid, 25 µCi/ml of radiolabeled sub-
strate (14C-U-L-leucine,  14C-U-L-proline,  14C-L-U-
glutamic acid or 35S-L-cystine, Amersham, U.K.), 100
mmol/l NaSCN or KSCN, 100 mmol/l mannitol, 0.1
mmol/l MgSO4 and 10 mmol/l Hepes (pH 7.4). The time
courses of amino acid uptake were measured under the
following two different experimental conditions: a) under
a sodium-gradient condition (NaSCN); and b) in the
absence of sodium-gradient (KSCN). At time intervals (30
s, 60 s, 90 s, etc), adding 5 ml of ice-cold stop solution
containing 150 mmol/l KSCN and 10 mmol/l Tris-Hepes
(pH 7.4) ended the incubation. The suspension was
immediately poured onto a pre-wetted Millipore filter
which was washed three times with 3 ml of ice-cold stop
solution, dissolved in 5 ml of scintillator Hisafe 3 (LKB
Products, Bromma, Sweden) and assessed in a Counter
Wallac 1409 (Pharmacia, Turku, Finland). Non-specific
binding to the filter was previously measured and sub-
tracted from the total uptake. Results were expressed as
pmol of amino acid uptake per mg of protein.
Kinetics of D-Galactose and amino acids uptake were eval-
uated as previously reported [15,16] in the different afore-
mentioned experimental conditions. Assays of uptake
were carried out in the presence of several concentrations
of substrate, from 0.025 until 7 mmol/l and at a fixed
transport time of 3 seconds. Maximal velocity (Vmax) was
expressed as pmol of substrate/mg protein in 3 seconds
and the transporter affinity constant (Kt) was expressed as
mmol/l.
Statistical study
Data were expressed as mean ± SEM. To analyze the
homogeneity among groups, Kruskall-Wallis test was
used, followed by multiple post-hoc comparisons using
Mann-Withney U tests with Bonferroni adjustment. Any p
value <0.05 was considered to be statistically significant.
Calculations were performed with SPSS program version
6.0 (SPSS Inc., Chicago, IL). The Sigma Plot Program (ver-
sion 3.02 for PC) was used to process data of the kinetics
of galactose and amino acids uptake by BBMVs.
Results
Histological examinations (day 15 of the experimental
period) confirmed the presence of cirrhosis in all animals
that had received CCl4 (CI and CI+IGF groups). All cir-
rhotic animals showed ascites (untreated cirrhotic ani-
mals, CI: 15.3 ± 2.4 ml, p < 0.001 vs control group; IGF-
treated cirrhotic group, CI+IGF: 8.1 ± 1.3, p < 0.05 vs CI
group) (Table 1).
Uptake of galactose and amino acids by jejunal BBMVs
Figures 1A and 2 show uptakes of D-Galactose, L-leucine,
L-proline, L-glutamic acid and L-cysteine by BBMVs.
Galactose and amino acids uptakes were assessed in the
presence or absence of sodium gradient. In absence of
sodium gradient, there were no differences between the
three experimental groups in all cases. In the presence of
sodium gradient, untreated cirrhotic animals had a signif-
icant lower uptake as compared to controls, whereas
BBMV from IGF-I-treated cirrhotic group presented
normal values not significantly different compared to
controls and significantly higher than those of BBMV
from untreated cirrhotic rats.
The kinetic studies of D-galactose and amino acid uptake
by BBMVs were assessed at 3 seconds in the presence of
different concentrations of substrates, from 0.01 to 5
mmol/l in a pool (n = 10 animals) of BBMVs from each
group. It was found that Vmax was significantly diminished
(p < 0.01) in untreated cirrhotic animals compared to CO
group for sugar and for three of the four amino acids
tested (Table 2). However, a significant recovery of this
parameter was assessed in CI+IGF group reaching normal
values in all cases.
On the other hand, untreated cirrhotic animals (CI)
showed an increased Kt (p < 0.01) compared to controls,
expressing a lower affinity of transporters for their sub-
strates. This parameter improved in cirrhotic rats treated
with IGF-I (Table 2).
Electron microscopy studies are summarised in Figure 3
and Table 3. Ultrastructural alterations in microvilli varied
from elongation to atrophy. Animals with compensated
cirrhosis had elongated and straight microvilli (Fig. 3B) as
has been previously reported [13,15]. Elongated micro-
villi were also found in a 40% of ascitic cirrhotic rats (Fig.
3C). However in 30% of animals with ascitic cirrhosis,
microvilli were shorter (Fig. 3E and 3F), irregular in shape,
Table 1: Body and liver weights (g) and estimated ascites (ml)
CO CI CI+IGF
Body weight (b.w.) (g) 507.3 ± 19.3 445.7 ± 26.5 435 ± 33.2
Liver weight (g) 14.55 ± 0.80 13.59 ± 1.32 14.58 ± 1.81
Liver weight / 100 g b.w 2.87 ± 0.12 3.05 ± 0.24 3.12 ± 0.21
Ascites (ml) - 15.3 ± 2.4 *** 8.1 ± 1.3 ** &
Values are mean ± SEM, n = 10; **p < 0.01, ***p < 0.001 CO vs 
another groups; &p < 0.05 CI vs CI+IGFBMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/12
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Uptake of D-Galactose into brush border membrane vesicles (BBMVs) Figure 1
Uptake of D-Galactose into brush border membrane vesicles (BBMVs) (A) Time course of D-galactose. *p < 0.05, 
**p < 0.01, ***p < 0.001 CO vs othergroups. (B) Kinetic study of the Na+-dependent for D-galactose uptake into BBMVs. 
Each point represents the mean of initial rate of D-galactose transport (SE was <10%) obtained from three different experi-
ments using a pool of BBMVs from 10 animals from each group.BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/12
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Kinetic studies of amino acid uptakes into brush border membrane vesicles (BBMVs) Figure 2
Kinetic studies of amino acid uptakes into brush border membrane vesicles (BBMVs) (A) Time course of L-leu-
cine (1.0 mM) uptake by brush border membrane vesicles (BBMVs); (B) Time course of L-cysteine (1.0 mM) uptake; (C) Time 
course of L-glutamic acid (1.0 mM) uptake and (D) Time course of L-proline (1.0 mM) uptake with (in the presence of NaSCN) 
or without (in the presence of KSCN) sodium-gradient. *p < 0.05, **p < 0.01, ***p < 0.001 vs CO. No differences between 
groups were found in Na+-independent transport for the four amino acids studied.
Table 2: Kinetic constants (Maximal velocity – Vmax- and the affinity transporter constant – Kt-) for galactose and amino acid uptake by 
BBMVs in the three experimental groups:
Nutrient Kinetic constants Control group (CO, n = 
10)
Untreated cirrhotic rats 
(CI, n = 10)
Cirrhotic rats treated with 
IGF-I (CI+IGF, n = 10)
D-galactose Vmax 3470 ± 30 2460 ± 24*** 3008 ± 45*
Kt 0.71 ± 0.01 1.03 ± 0.02** 0.78 ± 0.02
L-leucine Vmax 305 ± 19 210 ± 15** 283 ± 18
Kt 1.6 ± 0.1 2.0 ± 0.2** 1.1 ± 0.1
L-proline Vmax 165 ± 32 92 ± 7 159 ± 28
Kt 1.9 ± 0.2 3.3 ± 0.2*** 2.1 ± 0.1
L-glutamic acid Vmax 828 ± 23 545 ± 13*** 789 ± 18
Kt 0.6 ± 0.0 1.1 ± 0.0** 0.8 ± 0.0
L-cysteine Vmax 195 ± 26 105 ± 11*** 182 ± 19
Kt 1.9 ± 0.1 2.3 ± 0.2** 1.9 ± 0.1
Values are mean ± SEM, n = pool of BBMVs from 10 animals from each group. Vmax expressed as pmol of substrate/ mg protein × 3 seconds and Kt 
as mmol/l. *p < 0.05, **p < 0.01, ***p < 0.001 CO vs other groups.BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/12
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Alterations of jejunal microvilli Figure 3
Alterations of jejunal microvilli Electron microscopy of jejunal mucosa (× 10,000, magnification): (A) Microvilli from 
healthy controls; (B). Elongated microvilli described in animals with compensated cirrhosis [13,14]; (C). Elongated microvilli 
with degenerative lesions of membranes from ascitic cirrhotic rats (CI group); (D). Elongation and fusion of microvilli was 
found in 40% of untreated rats with ascitic cirrhosis (CI); (E) and (F) atrophy of microvilli was found in the remaining 60% of 
this group (CI). However, atrophy microvilli were not found in CI+IGF group (see (G) and (H)). Effect of IGF-I on microvilli in 
ascitic cirrhotic rats (CI+IGF group) (× 10,000, magnification): (G), area with mild elongated microvilli, and (H), quite normal 
epithelium instead of atrophy. Arrows show the increased density in actin microfilaments at the side of connection with the 
intermediate filaments network in microvilli from treated cirrhotic rats. Thus, the described alterations in untreated rats with 
ascitic cirrhosis (C, D, E and F) were partially improved by IGF-I treatment (G and H).BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/12
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partly clustered and more loosely packed than normal. In
the remaining rats enterocyte microvilli were longer and
often fused (Fig. 3D), had electron lucent cores and their
membrane was disrupted. Cirrhotic animals treated with
IGF-I had a tendency to normalize the morphology of
microvilli recovering normal size and electrondensity
(Fig. 3G). No microvilli with atrophy were found in this
group (CI+IGF) (Fig. 3H).
These results indicate the existence of an alteration in
sugar and amino acid transport by the jejunum associated
with atrophy of mucosa in rats with advanced cirrhosis.
Discussion
The main findings in this study were: 1) the evolution of
jejunal structure from a marked elongation in early stages
[13,15] of liver cirrhosis to atrophy and degeneration of
microvilli in advanced cirrhosis; 2) sugar and amino acid
absorption were similar to that observed in the very early
phase; and 3) the improvement of both morphological
and functional alterations after a two week-course of treat-
ment with low doses of IGF-I.
Over many years, morphological studies in the small
intestinal mucosa in patients with cirrhosis have been
reported [21]. Marked changes such as edema, inflamma-
tion and fibrosis of the villi have been described [21]. In
contrast, other studies found minimal changes or normal
mucosa. Thus, histological reports of the small intestine
in cirrhosis show wide variation [21]. The present study
shows the histological progression of microvilli overtime,
suggesting that the presence of mucosa atrophy does
occur in advanced cirrhosis with ascites. However, ultras-
trutural changes are present since early stages of liver cir-
rhosis. Alterations of this nature may well contribute to
malabsorption by altering carrier-substrate interaction, as
it has been demonstrated [13,15]. When cirrhosis is more
advanced and rats show ascites, microvilli tend to become
atrophied. In this stage, IGF-treatment was also able to
restore normal intestinal morphology and function.
In early stages of cirrhosis rats showed an elongation of
microvilli [22]. We proposed that this could explain the
reduced intestinal transport of nutrients because of an
altered position of the carriers in intestinal mucosa
[13,15,16]. In more advanced cirrhosis the atrophy of the
mucosa may in addition lead to a reduction in carrier
number, explaining the reductions of maximal velocity
(Vmax) and affinity of the transporters for their substrates
(expressed as increased Kt) (Table 2).
On the other hand, a question arises as to whether direct
toxicity of CCl4 to intestinal mucosa could contribute to
atrophy since alcohol is known to damage intestinal
mucosa as well as liver and pancreas [22]. In the present
work CCl4 was given by inhalation, and thus its deleteri-
ous effects were exerted on liver [18,22] and lung. In fact,
this toxic possibility has been reasonably ruled out by the
presence of similar levels of malondyaldehyde, a marker
of lipid peroxidation [23], in intestinal mucosa homoge-
nates from both controls and CCl4–treated rats (data not
shown).
According to previous studies [15,16,18], we postulate
that the reported morphological and functional altera-
tions in the jejunum could be due to IGF-I deficiency
occurring in liver cirrhosis. In fact, we have previously
shown that in this experimental model of advanced liver
cirrhosis, serum levels of IGF-I were significantly reduced
(35% of those found in healthy controls) [14].
The first change on enterocytes, already described [13,15],
seems to be the reduction of density in actin microfila-
ments at the site of connection with the intermediate fila-
ments network. The alterations of the electrondensity of
microvilli are reported to be due to a rearrangement of
cytoskeleton filaments [24]. Interestingly, IGF-I induces
marked changes in cell shape and cytoskeletal organiza-
tion in different cell lines [13,15,25,26]. The elongation
of microvilli could occur as a secondary adaptive hyper-
plasia to increase the absorptive surface, thus enhancing
the maximum absorptive capacities of the jejunum and
ileum, as it has been described after treatment with pred-
nisolone [27]. It is well known that in coeliac syndromes
a strict gluten-free diet produces a normalization of the
mucosa in few weeks [28,29]. In liver cirrhosis, portal
Table 3: Morphometric study of microvilli in animals with advanced liver cirrhosis.
Control group (CO) Untreated cirrhotic group (CI) Cirrhotic rats treated 
with IGF-I (CI+IGF)
elongated microvilli microvilli atrophy
Length of microvilli (µm) 1.66 ± 0.08 2.91 ± 0.31*** 0.81 ± 0.19*** 1.97 ± 0.24&
Values are mean ± SEM, n = 8, ***p < 0.001; CO vs other groups, &p < 0.05 CI vs CI+IGFBMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/12
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hypertension could be a pathogenic factor for intestinal
atrophy.
In our experiment the effect of IGF-I on microvilli of cir-
rhotic rats may be explained in two ways that are not
mutually exclusive themselves. On one hand, the amelio-
ration of liver function induced by IGF-I [18] may have a
secondary beneficial effect on intestinal morphology and
function. On the other hand, a direct effect of IGF-I on
microvilli is plausible since there is much evidence about
the trophic effect of IGF-I on jejunum [30,31] after small
bowel resection and in parenterally fed rats [32,33].
Conclusions
In conclusion, the relative early onset of intestinal dam-
age, similar to mild lesion of coeliac disease could be due
to different factors but the subsequent partial recovery is
attributable to IGF-I administration. These results rein-
force our previous observations of a beneficial effect of
IGF-I on intestinal structure and function in rats with liver
cirrhosis, acting not only in early but also in advanced
stages of chronic hepatic disease.
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